search
Back to results

A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II) (LOTUS II)

Primary Purpose

Female Infertility

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Dydrogesterone 30 mg
intravaginal progesterone gel 90 mg
Sponsored by
Abbott
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Female Infertility

Eligibility Criteria

19 Years - 41 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed informed consent;
  • Premenopausal females, age > 18 years < 42 years
  • Non-smokers. For females who were past smokers, they must have stopped tobacco usage for at least 3 months prior screening visit
  • Early follicular phase (Day 2-4) Follicle stimulating hormone (FSH) less than or equal to 15 IU/L and estradiol (E2)within normal limits at screening
  • luteinizing hormone (LH), prolactin (PRL), T (testosterone) and thyroid-stimulating hormone (TSH), within the normal limits for the clinical laboratory, or considered not clinically significant by the Investigator within 6 months prior or at screening
  • Documented history of infertility (e.g., unable to conceive for at least one year or for 6 months for women ≥ 38 years of age or bilateral tubal occlusion or absence)
  • Normal transvaginal ultrasound at screening (or within 14 days prior of screening) without evidence of clinically significant abnormality consistent with finding adequate for Assisted Reproductive Technology (ART) with respect to uterus and adnexa (no hydrosalpinx or clinically relevant uterine fibroids)
  • Subject is not pregnant , confirmed by negative pregnancy or by Investigator Judgement
  • Clinically indicated protocol for induction of IVF with a fresh embryo
  • Single or dual embryo transfer
  • BMI ≥ 18 and ≤ 30 kg/m2

Exclusion Criteria:

  • Evidence of cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurologic/psychiatric, allergy, recent major surgery (< 3 months), or other relevant diseases as revealed by history, physical examination and/or laboratory assessments which could limit participation in or completion of the study;
  • Acute urogenital disease
  • Known allergic reactions to progesterone products
  • Known allergic reactions to peanuts and peanut oil
  • Intake of àny experimental drug or any participation in any other clinical trial within 30 days prior to study start
  • Mental disability or any other lack of fitness, in the Investigator's opinion, to preclude subjects to participate in or to complete the study
  • Current or recent substance abuse, including alcohol and tobacco (Note: Patients who stopped tobacco usage at least 3 months prior to screening visit would be allowed)
  • History of chemotherapy or radiotherapy
  • Patients with more than 3 unsuccessful IVF attempts
  • Contraindication for pregnancy
  • Refusal or inability to comply with the requirements of the study protocol for any reason, including scheduled clinic visits and laboratory tests
  • History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages Acute urogenital disease

Sites / Locations

  • Melbourne IVF
  • IVF Australia - St George Private HospitalIVF Australia - St George Private Hospital
  • Univerité Catholique de Louvain, Cliniques universitaires Saint-Luc
  • Algemeen Ziekenhuis Jan Palfijn Gent
  • UZ Gent
  • Universitair Ziekenhuis Brussel
  • Peking University People's Hospital
  • Reproductive & Genetic Hospital of Citic -Xiangya
  • West China Second University Hospital
  • Sun Yat-Sen Memorial Hsopiatl, Sun Yat-Sen University
  • The Sixth Hospital of Sun Yat-Sen University
  • The First Affiliate Hospital of Anhui Medical University
  • The First Affiliated Hospital of Nanjing Medical University
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
  • First Affiliated Hospital of Zhengzhou University
  • Fertility Center Berlin
  • Bielefeld Fertility Center
  • Kinderwunschzentrum Dortmund
  • Universitäres Kinderwunschzentrum Lübeck
  • Queen Mary Hospital
  • United CIIGMA Hospital
  • MILANN (Bangalore Assisted Conception Center)
  • Apollo Hospitals - Bangalore
  • All India Institute of Medical Sciences
  • Max Hospital
  • Institute of Reproductive Medicine
  • Ajanta Research Center, Ajanta Hospital and IVF center
  • Inamdar Multispecialty Hospital
  • Shree Hospital and Diagnostic Centre
  • CJSC "Center of Family Medicine"
  • Scientific Research Center of Obstetrics, Gynecology and Perinatology n. a. Ac. V. I. Kulakova
  • CJSC "Nasledniki"
  • Saint-Petersburg State Budgetary Healtcare Institution "Maternity Hospital # 17"
  • Singapore General Hospital
  • Songklanagarind Hospital
  • Maharaj Nakorn Chiang Mai Hospital
  • Medical Centre of Infertility Treatment "Clinic of Professor Yuzko"
  • "NADIYA" Clinic
  • The Institute for Reproductive Medicine in Ukraine
  • "Mother and Child" clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Dydrogesterone tablets 3x10 mg

Crinone 8% intravaginal progesterone gel 90 mg

Arm Description

Dydrogesterone tablets 3x10 mg

Crinone 8% intravaginal progesterone gel 90 mg

Outcomes

Primary Outcome Measures

Percentage of Participants With Presence of Fetal Heart Beats at 12 Week's Gestation Determined by Transvaginal Ultrasound
Pregnancy rate defined as the presence of fetal heart beats at 12 weeks' gestation determined by transvaginal ultrasound.

Secondary Outcome Measures

Positive Pregnancy Test Rate (Percentage of Participants With a Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer)
Positive biochemical pregnancy test on Day 14 after embryo transfer
Rate of Successful Completion of Pregnancy (Percentage of Participants With a Live Birth)
Live birth rate (percentage of participants with a live birth)
Physical Examination Newborn (Number of Delivered Newborns That Are Male or Female)
The gender (number of delivered newborns that are male or female)

Full Information

First Posted
June 16, 2015
Last Updated
September 4, 2019
Sponsor
Abbott
Collaborators
PRA Health Sciences, Datamap
search

1. Study Identification

Unique Protocol Identification Number
NCT02491437
Brief Title
A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)
Acronym
LOTUS II
Official Title
A Randomized, Open-label, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
July 2015 (undefined)
Primary Completion Date
May 2017 (Actual)
Study Completion Date
May 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abbott
Collaborators
PRA Health Sciences, Datamap

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this randomized, two-arm and open label study is to demonstrate that the treatment of a daily dose of 3x10mg dydrogesterone orally is as effective and safe as the daily dose Crinone 8% intravaginal progesterone gel 90 mg for the luteal support in women who are unable to conceive a child and are undergoing IVF. The treatment will start on the day of oocyte retrieval and continue until pregnancy is negative or until week 12 gestation. Patients will be followed during treatment until 30 days after delivery to record any safety and tolerability data of the patient and their newborn (s).
Detailed Description
"This article has been accepted for publication in Human Reproduction published by Oxford University Press."

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Female Infertility

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1034 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dydrogesterone tablets 3x10 mg
Arm Type
Experimental
Arm Description
Dydrogesterone tablets 3x10 mg
Arm Title
Crinone 8% intravaginal progesterone gel 90 mg
Arm Type
Experimental
Arm Description
Crinone 8% intravaginal progesterone gel 90 mg
Intervention Type
Drug
Intervention Name(s)
Dydrogesterone 30 mg
Intervention Description
Oral Dydrogesterone 10 mg tablets tid
Intervention Type
Drug
Intervention Name(s)
intravaginal progesterone gel 90 mg
Other Intervention Name(s)
Crinone 8% intravaginal progesterone gel 90 mg
Primary Outcome Measure Information:
Title
Percentage of Participants With Presence of Fetal Heart Beats at 12 Week's Gestation Determined by Transvaginal Ultrasound
Description
Pregnancy rate defined as the presence of fetal heart beats at 12 weeks' gestation determined by transvaginal ultrasound.
Time Frame
12 weeks´ gestation
Secondary Outcome Measure Information:
Title
Positive Pregnancy Test Rate (Percentage of Participants With a Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer)
Description
Positive biochemical pregnancy test on Day 14 after embryo transfer
Time Frame
Day 14 after embryo transfer
Title
Rate of Successful Completion of Pregnancy (Percentage of Participants With a Live Birth)
Description
Live birth rate (percentage of participants with a live birth)
Time Frame
After delivery (about 9 months after IVF)
Title
Physical Examination Newborn (Number of Delivered Newborns That Are Male or Female)
Description
The gender (number of delivered newborns that are male or female)
Time Frame
After delivery (about 9 months after IVF)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
41 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed informed consent; Premenopausal females, age > 18 years < 42 years Non-smokers. For females who were past smokers, they must have stopped tobacco usage for at least 3 months prior screening visit Early follicular phase (Day 2-4) Follicle stimulating hormone (FSH) less than or equal to 15 IU/L and estradiol (E2)within normal limits at screening luteinizing hormone (LH), prolactin (PRL), T (testosterone) and thyroid-stimulating hormone (TSH), within the normal limits for the clinical laboratory, or considered not clinically significant by the Investigator within 6 months prior or at screening Documented history of infertility (e.g., unable to conceive for at least one year or for 6 months for women ≥ 38 years of age or bilateral tubal occlusion or absence) Normal transvaginal ultrasound at screening (or within 14 days prior of screening) without evidence of clinically significant abnormality consistent with finding adequate for Assisted Reproductive Technology (ART) with respect to uterus and adnexa (no hydrosalpinx or clinically relevant uterine fibroids) Subject is not pregnant , confirmed by negative pregnancy or by Investigator Judgement Clinically indicated protocol for induction of IVF with a fresh embryo Single or dual embryo transfer BMI ≥ 18 and ≤ 30 kg/m2 Exclusion Criteria: Evidence of cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurologic/psychiatric, allergy, recent major surgery (< 3 months), or other relevant diseases as revealed by history, physical examination and/or laboratory assessments which could limit participation in or completion of the study; Acute urogenital disease Known allergic reactions to progesterone products Known allergic reactions to peanuts and peanut oil Intake of àny experimental drug or any participation in any other clinical trial within 30 days prior to study start Mental disability or any other lack of fitness, in the Investigator's opinion, to preclude subjects to participate in or to complete the study Current or recent substance abuse, including alcohol and tobacco (Note: Patients who stopped tobacco usage at least 3 months prior to screening visit would be allowed) History of chemotherapy or radiotherapy Patients with more than 3 unsuccessful IVF attempts Contraindication for pregnancy Refusal or inability to comply with the requirements of the study protocol for any reason, including scheduled clinic visits and laboratory tests History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages Acute urogenital disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shreyansh Shah, MD
Organizational Affiliation
Abbott
Official's Role
Study Director
Facility Information:
Facility Name
Melbourne IVF
City
East Melbourne
ZIP/Postal Code
3002
Country
Australia
Facility Name
IVF Australia - St George Private HospitalIVF Australia - St George Private Hospital
City
Kogarah
ZIP/Postal Code
2217
Country
Australia
Facility Name
Univerité Catholique de Louvain, Cliniques universitaires Saint-Luc
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Facility Name
Algemeen Ziekenhuis Jan Palfijn Gent
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
UZ Gent
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Universitair Ziekenhuis Brussel
City
Jette
ZIP/Postal Code
1090
Country
Belgium
Facility Name
Peking University People's Hospital
City
Beijing
ZIP/Postal Code
100044
Country
China
Facility Name
Reproductive & Genetic Hospital of Citic -Xiangya
City
Changsha
ZIP/Postal Code
410008
Country
China
Facility Name
West China Second University Hospital
City
Chengdu
ZIP/Postal Code
610041
Country
China
Facility Name
Sun Yat-Sen Memorial Hsopiatl, Sun Yat-Sen University
City
Guangzhou
ZIP/Postal Code
510120
Country
China
Facility Name
The Sixth Hospital of Sun Yat-Sen University
City
Guangzhou
ZIP/Postal Code
510655
Country
China
Facility Name
The First Affiliate Hospital of Anhui Medical University
City
Hefei
ZIP/Postal Code
230022
Country
China
Facility Name
The First Affiliated Hospital of Nanjing Medical University
City
Nanjing
ZIP/Postal Code
210029
Country
China
Facility Name
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
City
Wuhan
ZIP/Postal Code
430030
Country
China
Facility Name
First Affiliated Hospital of Zhengzhou University
City
Zhengzhou
ZIP/Postal Code
450052
Country
China
Facility Name
Fertility Center Berlin
City
Berlin
ZIP/Postal Code
14050
Country
Germany
Facility Name
Bielefeld Fertility Center
City
Bielefeld
ZIP/Postal Code
33619
Country
Germany
Facility Name
Kinderwunschzentrum Dortmund
City
Dortmund
ZIP/Postal Code
44135
Country
Germany
Facility Name
Universitäres Kinderwunschzentrum Lübeck
City
Lübeck
ZIP/Postal Code
23538
Country
Germany
Facility Name
Queen Mary Hospital
City
Hong Kong
Country
Hong Kong
Facility Name
United CIIGMA Hospital
City
Aurangabad
ZIP/Postal Code
431005
Country
India
Facility Name
MILANN (Bangalore Assisted Conception Center)
City
Bangalore
ZIP/Postal Code
560001
Country
India
Facility Name
Apollo Hospitals - Bangalore
City
Bangalore
ZIP/Postal Code
560076
Country
India
Facility Name
All India Institute of Medical Sciences
City
Delhi
ZIP/Postal Code
110029
Country
India
Facility Name
Max Hospital
City
Delhi
ZIP/Postal Code
110057
Country
India
Facility Name
Institute of Reproductive Medicine
City
Kolkata
ZIP/Postal Code
700014
Country
India
Facility Name
Ajanta Research Center, Ajanta Hospital and IVF center
City
Lucknow
ZIP/Postal Code
226005
Country
India
Facility Name
Inamdar Multispecialty Hospital
City
Pune
ZIP/Postal Code
411002
Country
India
Facility Name
Shree Hospital and Diagnostic Centre
City
Pune
ZIP/Postal Code
411006
Country
India
Facility Name
CJSC "Center of Family Medicine"
City
Ekaterinburg
ZIP/Postal Code
620043
Country
Russian Federation
Facility Name
Scientific Research Center of Obstetrics, Gynecology and Perinatology n. a. Ac. V. I. Kulakova
City
Moscow
ZIP/Postal Code
117997
Country
Russian Federation
Facility Name
CJSC "Nasledniki"
City
Moscow
ZIP/Postal Code
119192
Country
Russian Federation
Facility Name
Saint-Petersburg State Budgetary Healtcare Institution "Maternity Hospital # 17"
City
Saint-Petersburg
ZIP/Postal Code
193174
Country
Russian Federation
Facility Name
Singapore General Hospital
City
Singapore
ZIP/Postal Code
169608
Country
Singapore
Facility Name
Songklanagarind Hospital
City
Bangkok
ZIP/Postal Code
90110
Country
Thailand
Facility Name
Maharaj Nakorn Chiang Mai Hospital
City
Chiang Mai
ZIP/Postal Code
50200
Country
Thailand
Facility Name
Medical Centre of Infertility Treatment "Clinic of Professor Yuzko"
City
Chernivtsi
ZIP/Postal Code
58022
Country
Ukraine
Facility Name
"NADIYA" Clinic
City
Kiev
ZIP/Postal Code
03037
Country
Ukraine
Facility Name
The Institute for Reproductive Medicine in Ukraine
City
Kiev
ZIP/Postal Code
04107
Country
Ukraine
Facility Name
"Mother and Child" clinic
City
Kiev
ZIP/Postal Code
0411
Country
Ukraine

12. IPD Sharing Statement

Citations:
PubMed Identifier
30304457
Citation
Griesinger G, Blockeel C, Sukhikh GT, Patki A, Dhorepatil B, Yang DZ, Chen ZJ, Kahler E, Pexman-Fieth C, Tournaye H. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018 Dec 1;33(12):2212-2221. doi: 10.1093/humrep/dey306.
Results Reference
derived

Learn more about this trial

A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)

We'll reach out to this number within 24 hrs